Compare Amphastar Pharmaceuticals Inc (AMPH) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs NRG Energy Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while NRG Energy Inc trades at $120.38 (market cap $24.83B). The key difference: NRG Energy Inc is far larger — about 28.7× Amphastar Pharmaceuticals Inc's market cap, and NRG Energy Inc pays a 1.61% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | NRG | |
|---|---|---|
Market Cap | $863.95M | $24.83B |
Sector | Health | Utilities |
52-Week High | $30.81 | $184.03 |
52-Week Low | $16.87 | $117.04 |
Enterprise Value | $1.26B | $48.79B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
NRG Energy trades at $118.13, down 0.77% on the day, with a bearish technical signal and recent earnings misses in Q1 and Q2 2026. The company reported Q2 2026 adjusted EBITDA of $1.2 billion, up 34% year-over-year, and is advancing a 1.2-GW Texas data-center power project to drive growth. Valuation metrics show a P/E of 30.76 and P/S of 0.72, with a net income margin of 2.56% for 2025.
The outlook is mixed: strong analyst consensus (69% buy ratings) and a $207.83 price target suggest upside, but technical weakness, rising debt, and execution risks on new projects pose challenges. Revenue growth to $33.1B in 2026 and strategic investments in data center demand support long-term potential, though interest costs and leverage require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
